Canada markets closed

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
250.86+1.16 (+0.46%)
At close: 04:00PM EDT
249.00 -1.86 (-0.74%)
After hours: 07:50PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • r
    reigles
    Have you guys ever heard of (http://Themaxgains.tech)? The picks on there are way better than AMGN
  • k
    keith
    New high coming soon.
  • S
    SamIAm
    Affirms full year guidance
  • S
    SamIAm
    They slightly lowered top line revenue guidance to account for the acquisition of CCXI. Always a second shoe drops with AMGN earnings report.
  • o
    oppedahl
    AMGN looks like it is about to drop. Be careful guys. I have been reading (http://Achieverspot.tech) and their stocks have been doing way better.
  • E
    EJ
    Half their cash for a 1 trick pony and $65B in debt.
  • S
    Steve
    Perfect time to invest in AMGN. Write call options if you are nervous. Watch IBB and XBI.
    AND don't forget another increase in dividend to be announced on or about December 15. I expect minimum of 10% increase to $8.50+ per year.
  • p
    paul
    Amgen Battles With the IRS Over Its $10.7 Billion Tax Bill
    reported today inWall Street Journal
  • S
    SamIAm
    I hope they don't disappoint us AGAIN!
  • k
    keith
    AMGN needs to buy CRDF, Hello AMGN get it before Pfizer does.
  • A
    A.I.R.
    Bertrand delsuc:

    $AMGN gives up in BCMA race

    Pavurutamab (AMG 701)

    Clinical development of pavurutamab an anti-B-cell maturation antigen (BCMA) HLE BiTE molecule being investigated for the treatment of multiple myeloma, has been discontinued for strategic reasons.

    Loncar:

    Going to be nearly impossible for bi-specifics to compete with CAR-T efficacy in BCMA. Hard to see where they fit in.

    Rennert:

    also hard to see how other CAR-BCMA programs compete once JNJ gets the wheels turning on cilta-cel

    Thoughts peter?
  • k
    kite
    There is a new virus (LayV)found in china and it is treated with antiviral. There is a future for TPOXX....More opportunity in future....
  • S
    SamIAm
    Big miss at LLY may lean on pharmaceuticals
  • S
    SamIAm
    Beat on top and bottom line
  • R
    Rob
    I know a guy that was buying AMGN on a weekly when it was trading at $1.00 lol
  • S
    SamIAm
    If management blames competitors again I think I'll scream 😱
  • N
    Nova
    $AMZN conversation
    $AMGN In the recent reporting quarter: 17.23% of institutions made no changes to their position.
  • m
    michael k
    Long time Amgen holder since 2001. I hate to say it but every time they get close to a double top they always break down and never break out. They have a history of this. They should be a $300 plus stock by
    Now but it just doesn't happen... sadly there always seem to be an excuse as to why. Since I bought in at $68 in 2001 and based on that price and what the dividend is now that's about a 12% return on original investment. However, they still should be trading at a 6 to 8x from where I bought it. Oh well maybe one day they will break to the upside "when someone bigger acquires them"...
  • j
    j
    $ARWR conversation
    Credit Truth on twitter:
    Notable that $AMGN is demonstrating a new level of confidence in $ARWR TRiM
    Trade mark sign
    by their manner of promoting progress with Lipoprotein(a) w/ AMG-890 formerly Arrowhead’s ARO-LPA https://amgenscience.com/features/10-things-to-know-about-lipoproteina/
    Seems this blockbuster drug is moving quickly enough to merit this Amgen PR.
    https://www.amgenscience.com/features/10-things-to-know-about-lipoproteina/
    10 Things to Know About Lipoprotein(a) - Amgen Science
    www.amgenscience.com